Checkpoint therapies like Keytruda, Opdivo, and Imfinzi are expanding from late-stage to early-stage cancer treatment, with ...

The CDC will no longer recommend routine Covid-19 vaccines for healthy kids and pregnant women after HHS Secretary Robert F.

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

Novo Nordisk warned the US government not to impose pharma-specific tariffs, but instead to tax illegal importers of ...

As of Thursday morning, just over 300 entries out of at least 950 public comments have been released by the Department of ...

Prothena abandons birtamimab after Phase 3 amyloidosis trial failure, plans layoffs. Drug previously failed mid-stage trial.

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

The companies said Thursday that they voluntarily withdrew the accelerated approval request for patritumab deruxtecan in ...

Strand Therapeutics reports early positive data for STX-001, a self-replicating mRNA cancer therapy, showing safety and ...

Sanofi partners in Vietnam, Almac hits £1B sales, Quadria raises $1.07B, CurifyLabs gets funding, BrainStorm signs with ...

Indy biotech Syndeio launches with $90M, led by CEO Derek Small, to develop NMDA receptor drugs for depression & Alzheimer's, ...

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a ...